Bernett MJ - Search Results

1

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy.

Yadav R, Schubbert S, Holder PG, Chiang EY, Kiabi N, Bogaert L, Leung I, Rashid R, Avery KN, Bonzon C, Desjarlais JR, Sanjabi S, Sharma A, Lepherd M, Shelton A, Chan P, Liu Y, Joslyn L, Hosseini I, Stefanich EG, Kamath AV, Bernett MJ, Shivva V. Yadav R, et al. Among authors: bernett mj. Front Pharmacol. 2024 Jun 3;15:1380000. doi: 10.3389/fphar.2024.1380000. eCollection 2024. Front Pharmacol. 2024. PMID: 38887559 Free PMC article.

2

Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics.

Lu D, Yadav R, Holder P, Chiang E, Sanjabi S, Poon V, Bernett M, Varma R, Liu K, Leung I, Bogaert L, Desjarlais J, Shivva V, Hosseini I, Ramanujan S. Lu D, et al. Eur J Pharm Sci. 2023 Jul 1;186:106450. doi: 10.1016/j.ejps.2023.106450. Epub 2023 Apr 20. Eur J Pharm Sci. 2023. PMID: 37084985 Free article.

3

IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion.

Li J, Clark R, Slaga D, Avery K, Liu K, Schubbert S, Varma R, Chiang E, Totpal K, Bernett MJ, Holder PG, Junttila TT. Li J, et al. Among authors: bernett mj. Mol Cancer Ther. 2024 Sep 4;23(9):1305-1316. doi: 10.1158/1535-7163.MCT-23-0910. Mol Cancer Ther. 2024. PMID: 38739434

4

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.

Chu SY, Horton HM, Pong E, Leung IW, Chen H, Nguyen DH, Bautista C, Muchhal US, Bernett MJ, Moore GL, Szymkowski DE, Desjarlais JR. Chu SY, et al. Among authors: bernett mj. J Allergy Clin Immunol. 2012 Apr;129(4):1102-15. doi: 10.1016/j.jaci.2011.11.029. Epub 2012 Jan 16. J Allergy Clin Immunol. 2012. PMID: 22257644

5

Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.

Bernett MJ, Chu SY, Leung I, Moore GL, Lee SH, Pong E, Chen H, Phung S, Muchhal US, Horton HM, Lazar GA, Desjarlais JR, Szymkowski DE. Bernett MJ, et al. MAbs. 2013 May-Jun;5(3):384-96. doi: 10.4161/mabs.23976. Epub 2013 Apr 2. MAbs. 2013. PMID: 23549103 Free PMC article.

6

A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.

Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen DT, Jacinto J, Eivazi A, Nisthal A, Diaz JE, Chu SY, Muchhal US, Desjarlais JR. Moore GL, et al. Among authors: bernett mj. Methods. 2019 Feb 1;154:38-50. doi: 10.1016/j.ymeth.2018.10.006. Epub 2018 Oct 23. Methods. 2019. PMID: 30366098 Free article.

7

Engineering fully human monoclonal antibodies from murine variable regions.

Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA. Bernett MJ, et al. J Mol Biol. 2010 Mar 12;396(5):1474-90. doi: 10.1016/j.jmb.2009.12.046. Epub 2010 Jan 4. J Mol Biol. 2010. PMID: 20045416

8

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA. Horton HM, et al. Among authors: bernett mj. Blood. 2010 Oct 21;116(16):3004-12. doi: 10.1182/blood-2010-01-265280. Epub 2010 Jul 8. Blood. 2010. PMID: 20616215 Free article.

9

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.

Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, Stevens J, Case R, Pearson JT, Liu S, McElroy PL, Canon J, Desjarlais JR, Coxon A, Balazs M, Nolan-Stevaux O. Zuch de Zafra CL, et al. Among authors: bernett mj. Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27. Clin Cancer Res. 2019. PMID: 30918018

10

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA. Horton HM, et al. Among authors: bernett mj. Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268. Cancer Res. 2008. PMID: 18829563

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters